In a landmark move for UK patients with obesity, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved ...

GLP-1 agonist injections, although originally developed to treat type 2 diabetes, have changed how we approach obesity.1 The two main types now in use—semaglutide (Wegovy), produced by Novo Nordisk, ...

The new rules introduce a fast-track notification route, enabling quicker starts for lower-risk trials and maintaining safety ...

A ‘triple-strength’ weight-loss jab has just been approved by NHS watchdog Medicines and Healthcare products Regulatory ...

Study confirms vaccine being used in global efforts to achieve and sustain polio eradication is successfully interrupting polio outbreaks whilst ...

Novo Nordisk’s Wegovy (semaglutide injection) has received a new approval from the Medicines and Healthcare products ...

The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...

UK MHRA approves up to 7.2mg dose of semaglutide for patients with obesity only: United Kingdom Saturday, January 17, 2026, 13:00 Hrs [IST] The UK Medicines and Healthcare product ...

The MHRA has authorised GSK’s Nucala (mepolizumab) in the UK as an add‑on maintenance treatment for adults with uncontrolled ...

The MHRA has strengthened addiction warnings for Z-drugs, benzodiazepines, and gabapentinoids after a review found risks of ...

Great Britain is entering a new era of MedTech regulation, with major pre-market changes expected that are designed to ...

The lifecycle of a medical device is under renewed regulatory and commercial scrutiny. Although lifetime expectations are not ...